1-2 of 2
Chantal E. Hargreaves
Close
Sort by
Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Clinical Trials & Observations
Jonathan C. Strefford, Malgorzata Nowicka, Chantal E. Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V. Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N. Potter, Matthew J. J. Rose-Zerilli, Laurie H. Sehn, Marek Trněný, Umberto Vitolo, Christopher R. Bolen, Christian Klein, Andrea Knapp, Mikkel Z. Oestergaard, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2935–2944.
https://doi.org/10.1182/bloodadvances.2020003985
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data